Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

      Evogene Logo

      News provided by

      Evogene

      Nov 19, 2026, 07:00 ET

      Share this article

      Share this article


      Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria

      REHOVOT, Israel, Nov. 19, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a computational chemistry company leveraging proprietary AI-driven technologies to design and develop novel small molecules for the pharmaceutical and agricultural industries, today reported its financial results for the third quarter and first nine months of 2026, and provided an update on its business activities.

      Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.

      The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (For more information, please see our PR from 28, October 2026)

      The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential. (For more information, please see our PR from 17, November 2026)

      The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "

      Financial Results and Analysis

      Cash Position

      As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period.

      Revenues

      Revenues for the nine months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026.

      Research and Development Expenses

      Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuations in the USD/NIS exchange rate, between the periods.

      Sales and Marketing Expenses

      Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million, compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million, compared to approximately $0.4 million in the third quarter of 2025, primarily due to lower sales and marketing expenses at Casterra and AgPlenus.

      General and Administrative Expenses

      General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly by transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to corporate governance and shareholders matters. These costs totaled approximately $0.4 million and $0.3 million during the nine-month and three-month periods ended September 30, 2026, respectively.

      Financing Expenses (Income), Net

      Financing expenses, net, for the nine months of 2026 were approximately $1.6 million, compared to financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the Company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176 thousand, compared to approximately $79 thousand in the corresponding period of 2025, with no material change between the periods.

      Loss from Discontinued Operations

      Loss from discontinued operations, net, for the nine months of 2026 was approximately $0.5 million, compared to an income from discontinued operations, net, of approximately $4.0 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025.

      Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8.0 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million, compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025, as discussed above.

      About Evogene Ltd.

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

      For more information, please visit www.evogene.com. 

      About AgPlenus Ltd. 

      AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs. 

      For more information, please visit www.agplenus.com

      Forward-Looking Statements

      This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its  discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.

      Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy  terrorist groups, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene's and its subsidiaries' reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene's board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene's actual results to differ from those reflected in its forward-looking statements, please see "Item 3.D. Risk Factors" in Evogene's Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.

      Investor Relations Contact:

      [email protected]
      Tel: +972-8-9311901

      CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

      U.S. dollars in thousands




      September 30,


      December 31,



      2026


      2025



      Unaudited



      ASSETS





      CURRENT ASSETS:





      Cash and cash equivalents


      $               8,571


      $               12,956

      Restricted cash


      33


      32

      Short-term bank deposits


      655


      -

      Trade receivables


      232


      317

      Other receivables and prepaid expenses


      1,181


      1,565

      Deferred expenses related to issuance of warrants


      -


      551

      Inventories


      65


      210








      10,737


      15,631

      LONG-TERM ASSETS:





      Long-term deposits and other receivables


      5


      571

      Investment accounted for using the equity method


      -


      43

      Deferred expenses related to issuance of warrants


      -


      1,165

      Right-of-use-assets


      1,446


      1,824

      Property, plant and equipment, net


      446


      812








      1,897


      4,415






      TOTAL ASSETS


      $               12,634


      $               20,046






      LIABILITIES AND EQUITY










      CURRENT LIABILITIES:





      Trade payables


      $                 593


      $                639

      Employees and payroll accruals


      703


      861

      Lease liabilities


      618


      716

      Liabilities in respect of government grants


      142


      56

      Deferred revenues and other advances


      21


      17

      Warrants and pre-funded warrants liability


      496


      706

      Other payables


      389


      449








      2,962


      3,444

      LONG-TERM LIABILITIES:





      Lease liabilities


      1,287


      1,482

      Liabilities in respect of government grants


      3,082


      3,073

      Deferred revenues and other advances


      60


      72








      4,429


      4,627






      TOTAL LIABILITIES


      $             7,391


      $             8,071

      CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

      U.S. dollars in thousands



      SHAREHOLDERS' EQUITY:





      Ordinary shares of NIS 0.2 par value:

      Authorized − 30,000,000 ordinary shares; Issued and
      outstanding – 18,052,405 ordinary shares on September
      30, 2026 and 8,718,193 ordinary shares on December
      31, 2025


      1,103


      488

      Share premium and other capital reserves


      288,212


      281,986

      Accumulated deficit


      (293,043)


      (282,556)






      Equity attributable to equity holders of the Company


      (3,728)


      (82)






      Non-controlling interests


      8,971


      12,057






      TOTAL EQUITY


      5,243


      11,975






      TOTAL LIABILITIES AND EQUITY


      $             12,634


      $             20,046

      CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

      U.S. dollars in thousands (except share and per share amounts)




      Nine months ended

      September 30,


      Three months ended

      September 30,


      Year ended

       December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited












      Revenues


      $       822


      $       3,189


      $      141


      $      312


      $      3,503












      Cost of revenues:











         Inventory impairment


      -


      -


      -


      -


      2,180

         Other cost of revenues


      428


      1,810


      92


      157


      1,914

      Total Cost of Revenues


      428


      1,810


      92


      157


      4,094












      Gross profit


      394


      1,379


      49


      155


      (591)

      Operating expenses:






















      Research and development, net


      4,466


      4,635


      1,528


      1,133


      6,262

      Sales and marketing


      908


      1,061


      200


      358


      1,359

      General and administrative


      3,096


      3,154


      1,112


      1,091


      4,021

      Other expenses (income)


      293


      (191)


      191


      -


      (205)












      Total operating expenses, net


      8,763


      8,659


      3,031


      2,582


      11,437












      Operating loss


      (8,369)


      (7,280)


      (2,982)


      (2,427)


      (12,028)












      Financing income


      2,559


      2,352


      255


      513


      2,618

      Financing expenses


      (4,124)


      (1,445)


      (79)


      (434)


      (1,841)












      Financing income (expenses), net


      (1,565)


      907


      176


      79


      777












      Share of loss from equity accounted investment


      ((43


      (82)


      -


      (16)


      (39)












      Loss before taxes on income


      (9,977)


      (6,455)


      (2,806)


      (2,364)


      (11,290)

      Taxes on income (tax benefit)


      -


      1


      -


      -


      1

      Loss from continuing operations


      (9,977)


      (6,456)


      (2,806)


      (2,364)


      (11,291)

      Income (loss) from discontinued operations, net


      (548)


      3,983


      (56)


      7,561


      3,464












      Net income (loss)


      $     (10,525)


      $     (2,473)


      $    (2,862)


      $   5,197


      $   (7,827)












      Attributable to:











      Equity holders of the Company


      $     (10,487)


      $     (3,176)


      $   (2,849)


      $   3,874


      (8,485)

      Non-controlling interests


      (38)


      703


      (13)


      1,323


      658














      $         (10,525)


      $     (2,473)


      $   (2,862)


      $   5,197


      $  (7,827)

      Basic and diluted loss per share from
      continuing operations, attributable to equity
      holders of the Company


      $       (0.75)


      $       (0.84)


      $     (0.17)


      $     (0.27)


      $      (1.41)

      Basic and diluted loss per share from
      discontinued operations, attributable to
      equity holders of the Company


      $       (0.04)


      $          0.42


      $     (0.00)


      $        0.71


      $      0.33












      Weighted average number of shares used in
      computing basic and diluted loss per share


      13,245,869


      7,588,486


      16,894,446


      8,716,424


      7,874,039


           (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
            discontinued operations.

      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

      U.S. dollars in thousands



      Nine months ended

      September 30,


      Three months ended

      September 30,



      Year ended

      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited

          Cash flows from operating activities






















      Loss from continuing operations


      $    (9,977)


      $    (6,456)


      $    (2,806)


      $    (2,364)


      $  (11,291)












      Adjustments to reconcile loss to net cash used in operating activities:


















      Adjustments to the profit or loss items:






















      Depreciation of property, plant and equipment and right-of-use-assets


      501


      748


      167


      241


      971

      Impairment of Property, Plant and Equipment


      116


      -


      -


      -


      -

      Inventory impairment


      -


      -


      -


      -


      2,180

      Share-based compensation


      80)


      570


      (13)


      125


      728

      Remeasurement of Convertible SAFE


      -


      (371)


      -


      (26)


      (371)

      Net financing expenses (income)


      (73)


      21


      (81)


      (135)


      (28)

      Loss (gain) from sale of property, plant and equipment


      (17)


      (192)


      (3)


      2


      (205)

      Revaluation of government grants


      27


      24


      18


      24


      40

      Amortization of deferred expenses related to issuance of warrants


      1,716


      989


      -


      333


      1,323

      Remeasurement of pre-funded warrants and warrants


      (2,271)


      (1,664)


      (163)


      (346)


      (1,781)

      Expenses related to warrants inducement transaction


      2,095


      -


      -


      -


      -

      Share of loss of an associate


      43


      82


      -


      15


      39

      Allowance for doubtful accounts


      78


      -


      78


      -


      -

      Investment in sub-lease


      194


      -


      194


      -


      -

      Taxes on income (tax benefit)


      -


      1


      -


      -


      (6)














      2,489


      208


      197


      233


      2,890

      Changes in asset and liability items:

       











      Decrease in trade receivables


      7


      667


      74


      730


      665

      Decrease (increase) in other receivables and prepaid expenses


      (114)


      870


      (388)


      (417)


      958

      Decrease (increase) in inventories


      145


      (740)


      28


      (139)


      (1,019)

      Increase (decrease) in trade payables


      62


      (195)


      187


      (31)


      (40)

      Decrease in employees and payroll accruals


      (143)


      (335)


      (204)


      (226)


      (494)

      Increase (decrease) in other payables


      16


      (343)


      117


      (45)


      (344)

      Decrease in deferred revenues and other advances


      (8)


      (356)


      (5)


      (5)


      (361)














      (35)


      (432)


      (191)


      (133)


      (635)

           (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
            discontinued operations.

      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

      U.S. dollars in thousands




      Nine months ended

      September 30,


      Three months ended

      September 30,


      Year ended

      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited

      Cash received (paid) during the period for:






















      Interest received


      246


      221


      46


      45


      338

      Interest paid


      (104)


      (221)


      (20)


      (70)


      (256)

      Taxes paid


      (5)


      (11)


      -


      -


      (11)












      Net cash used in continuing operating activities


      (7,386)


      (6,691)


      (2,774)


      (2,289)


      (8,965)












      Net cash provided by (used in) discontinued operations activities


      (287)


      (4,125)


      13


      (1,044)


      (4,537)












      Net cash used in operating activities


      $   (7,673)


      $   (10,816)


      $    (2,761)


      $    (3,333)


      $   (13,502)












      Cash flows from investing activities:

































      Purchase of property, plant and equipment


      $         (13(


      (129)


      (2)


      (7)


      $      (199)

      Proceeds from sale of property, plant and equipment


      115


      10


      3


      10


      78

      Proceeds from finance sub-lease asset


      17


      29


      -


      12


      52

      Investment in bank deposits, net


      (655)


      (3,700)


      (655)


      (2,699)


      (1)












      Net cash provided by (used in) continuing investing activities


      (536)


      (3,790)


      (654)


      (2,684)


      (70)












      Net cash provided by (used in) discontinued investing activities


      483


      11,265


      483


      13,593


      17,808












      Net cash provided by (used in) investing activities


      $           53) (


      $    7,475


      $   (171)


      $   10,909


      $     17,738












           (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
           discontinued operations.

      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

      U.S. dollars in thousands




      Nine months ended

      September 30,


      Three months ended

      September 30,


      Year ended

      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)




      Unaudited


      Audited


      Cash flows from financing activities:
























      Proceeds from issuance of ordinary shares,
      net of issuance expenses


      3,155


      4,283


      2,350


      -


      4,283


      Proceeds from issuance of ordinary shares
      in warrant inducement transaction, net of
      issuance expenses


      3,206


      -


      -


      -


      -


      Repayment of lease liability


      (334)


      (315)


      (121)


      (87)


      (423)


      Dividend paid by subsidiary


      (2,672)


      -


      -


      -


      -


      Repayment of convertible SAFE


      -


      (10,000)


      -


      (10,000)


      (10,000)


      Proceeds from government grants


      101


      -


      -


      -


      -


      Repayment of government grants


      (34)


      (122)


      (14)


      -


      (244)














      Net cash provided by (used in) continuing
      financing activities


      3,422


      (6,154)


      2,215


      (10,087)


      (6,384)














      Net cash used in discontinued financing
      activities


      (80)


      (192)


      (30)


      (249)


      (218)














      Net cash provided by (used in) financing
      activities


      $       3,342


      $    (6,346)


      $   2,185


      $   (10,336)


      $     (6,602)














      Exchange rate differences - cash and cash
      equivalent balances


      (1)


      12


      2


      (13)


      21














      Decrease in cash and cash equivalents


      (4,385)


      (9,675)


      (745)


      (2,773)


      (2,345)














      Cash and cash equivalents, beginning of the
      period


      12,956


      15,301


      9,316


      8,329


      15,301


      Cash and cash equivalents presented in
      assets held for sale


      -


      -


      -


      70


      -














      Cash and cash equivalents, end of the period


      $    8,571


      $    5,626


      $    8,571


      $    5,626


      $    12,956














      Significant non-cash activities












      Acquisition of property, plant and
      equipment


      $            -


      $            2


      $        -


      $           -


      $         2


      Right-of-use asset recognized with
      corresponding lease liability


      $          33


      $         207


      $-


      $      -


      $      207


      Exercise of pre-funded warrants


      $         -


      $         389


      $          -


      $          -


      $      389


      Derecognition of property, plant and
      equipment under a finance lease


      $          -


      $           13


      $          -


      $                -


      13         $



           (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
            discontinued operations.

      SOURCE Evogene

      Modal title

      Also from this source

      Evogene Schedules Third Quarter 2026 Financial Results Release

      Evogene Schedules Third Quarter 2026 Financial Results Release

      Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules...

      Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

      Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules ...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Computer & Electronics

      Computer & Electronics

      Chemical

      Chemical

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.